Multidrug-Resistant Transporter Mdr1p-Mediated Uptake of a Novel Antifungal Compound
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The activity of many anti-infectious drugs has been compromised by the evolution of multidrug-resistant (MDR) pathogens. For life-threatening fungal infections, such as those caused by Candida albicans , overexpression of MDR1 , which encodes an MDR efflux pump of the major facilitator superfamily (MFS), often confers resistance to chemically unrelated substances, including the most commonly used azole antifungals. As the development of new and efficacious antifungals has lagged far behind the growing emergence of resistant strains, it is imperative to develop strategies to overcome multidrug resistance. Previous advances have been mainly to deploy combinational therapy to restore azole susceptibility, which, however, requires coordination of two or more compounds. We observed a unique phenotype in which Mdr1p facilitates the uptake of a specific class of compounds. Among them, we describe a novel antifungal small molecule, bis[1,6-a:5′,6′-g]quinolizinium 8-methyl-salt (BQM) (U.S. patent application no. 61/793,090,2013), that has potent and broad antifungal activity. Notably, BQM exploits the MDR phenotype in C. albicans to promote the inhibitory effect. Rather than causing an antagonism of MDR strains, it exhibits a highly potentiated activity against a collection of clinical isolates and lab strains that overexpress MDR1 . The activity of BQM against MDR1 -overexpressing isolates is due to its facilitated intracellular accumulation. Microarray comparisons showed an extensive upregulation of MDR1 as well as polyamine transporter genes in a fluconazole-resistant strain. We then demonstrated that the polyamine transporters augment the accumulation of BQM. Importantly, BQM had greater activity than fluconazole and itraconazole against various fungal pathogens, including MDR Aspergillus fumigatus . Thus, our findings offer a paradigm shift to overcome MDR and the promise of improving antifungal treatment, especially in MDR pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Emerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811 · cited 1×
“The incidence of candidiasis has increased sharply over the past few decades, primarily due to hospital interventions such as cancer chemotherapy, surgery, organ/bone marrow transplantation, and indwelling devices (3).”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 2×
“Injection of fungal pathogens and antifungal drugs was performed as described previously (25, 26).”
BackgroundMethodEvolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355 · cited 9×
“3A and B), consistent with previous findings that MDR1 overexpression due to MRR1 gain of expression contributes to fluconazole resistance in CaMDR (14, 18).”
BackgroundInfluentialA Human-Curated Annotation of the Candida albicans Genome
Braun, B. R., van het Hoog, M., d'Enfert, C., Martchenko, M., Dungan, J., Kuo, A., Inglis, D. O., Uhl, M. A., Hogues, H., Berriman, M., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010001 · Cited by 342
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 2×
“CaS has minimal levels of MDR1 and was initially isolated from an HIV patient with oral candidiasis, while strain CaMDR was isolated from the same patient after a 2-year treatment with fluconazole and overexpressed MDR1 (14, 19, 27).”
BackgroundThe evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Yeast Model Uncovers Dual Roles of Mitochondria in the Action of Artemisinin
Li, W., Mo, W., Shen, D., Sun, L., Wang, J., Lu, S., Gitschier, J. M., & Zhou, B. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010036 · Cited by 304
Shingu-Vazquez, M., & Traven, A. (2011) · Eukaryotic Cell · doi:10.1128/ec.05184-11 · Cited by 209
Evolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151
Population genomics of drug resistance in Candida albicans
Cowen, L. E., Nantel, A., Whiteway, M. S., Thomas, D. Y., Tessier, D. C., Kohn, L. M., & Anderson, J. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102291099 · Cited by 140 · cited 1×
“neered overexpression of MDR1 increased resistance (19, 20).”
BackgroundSchubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135 · cited 10×
“Transcriptional profiling of in vivo DNA binding studies showed that a constitutively active Mrr1p binds to and upregulates numerous direct target genes in addition to MDR1 (14).”
BackgroundInfluentialTsao, S., Rahkhoodaee, F., & Raymond, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00926-08 · Cited by 126
Azole Drugs Are Imported By Facilitated Diffusion in Candida albicans and Other Pathogenic Fungi
Mansfield, B. E., Oltean, H. N., Oliver, B. G., Hoot, S. J., Leyde, S. E., Hedstrom, L., & White, T. C. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001126 · Cited by 111
Estimating the Cost of Nosocomial Candidemia in the United States
Miller, L. G., Hajjeh, R. A., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319613 · Cited by 109
Holmes, A. R., Keniya, M. V., Ivnitski-Steele, I., Monk, B. C., Lamping, E., Sklar, L. A., & Cannon, R. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05706-11 · Cited by 106
MacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-09 · Cited by 98
Bambach, A., Fernandes, M. P., Ghosh, A., Kruppa, M., Alex, D., Li, D., Fonzi, W. A., Chauhan, N., Sun, N., Agrellos, O. A., et al. (2009) · Eukaryotic Cell · doi:10.1128/ec.00066-09 · Cited by 95
Self-citationSun, N., Fonzi, W., Chen, H., She, X., Zhang, L., Zhang, L., & Calderone, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-12 · Cited by 94
Self-citationLi, D., Chen, H., Florentino, A., Alex, D., Sikorski, P., Fonzi, W. A., & Calderone, R. (2011) · Eukaryotic Cell · doi:10.1128/ec.00303-10 · Cited by 91 · cited 2×
“albicans suggest a promising avenue for further research on their exploitation as drug targets (23, 24, 42, 43, 45).”
BackgroundMethodSelf-citationRognon, B., Kozovska, Z., Coste, A. T., Pardini, G., & Sanglard, D. (2006) · Microbiology · doi:10.1099/mic.0.29277-0 · Cited by 71
Involvement of Candida albicans NADH dehydrogenase complex I in filamentation
McDonough, J. A., Bhattacherjee, V., Sadlon, T., & Hostetter, M. K. (2002) · Fungal Genetics and Biology · doi:10.1016/s1087-1845(02)00007-5 · Cited by 61 · cited 2×
“albicans suggest a promising avenue for further research on their exploitation as drug targets (23, 24, 42, 43, 45).”
BackgroundInvolvement of Candida albicans pyruvate dehydrogenase complex protein X (Pdx1) in filamentation
Vellucci, V. F., Gygax, S. E., & Hostetter, M. K. (2007) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2006.12.003 · Cited by 40
Cited by
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Exploiting mitochondria as targets for the development of new antifungals
Li, D., & Calderone, R. (2017) · Virulence · doi:10.1080/21505594.2016.1188235 · Cited by 67
Self-citationBerberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p
Tong, Y., Zhang, J., Sun, N., Wang, X.-M., Wei, Q., Zhang, Y., Huang, R., Pu, Y., Dai, H., Ren, B., et al. (2021) · Science Bulletin · doi:10.1016/j.scib.2020.12.035 · Cited by 70
Self-citationRepurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity
Sun, N., Li, D., Zhang, Y., Killeen, K., Groutas, W., & Calderone, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17147-x · Cited by 36
Self-citationFunctional diversity of complex I subunits in Candida albicans mitochondria
Li, D., She, X., & Calderone, R. (2016) · Current Genetics · doi:10.1007/s00294-015-0518-6 · Cited by 27
“The cause of hypersusceptibility to fluconazole varies among the CI mutants (Sun et al. 2013b).”
Self-citation
Metadata
- Authors
- Sun, N., Li, D., Fonzi, W., Li, X., Zhang, L., & Calderone, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-12
- Volume
- 57
- Issue
- 12
- Pages
- 5931-5939
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2165690142
- Cited by
- 30
- References
- 28
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.